Botanix Pharmaceuticals' (ASX:BOT) stock slump is backed by no "good" company-specific reason aside from broader macroeconomic factors, said Euroz Hartleys in a Thursday note.
The stock has seen continuous sessions of losses since it reported a wider fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.
The research firm believes the company's half-year results were unsurprising, and the extent of the stock's decline remains "puzzling."
The company will see a negligible financial impact from the newly imposed 25% tariff on Canadian exports, the note added.
The research firm maintained its buy rating and price target of AU$0.55 on Botanix Pharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.